A new coumarin compound DCH combats methicillin-resistant Staphylococcus aureus biofilm by targeting arginine...

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• Staphylococcus aureus infections, particularly methicillin-resistant strains (MRSA), are challenging due to biofilm formation and antibiotic resistance.
• There is an urgent need for novel therapeutic agents to combat persistent MRSA infections and their associated biofilms.

Purpose of the Study:

• To identify and characterize a new compound with potent anti-MRSA biofilm activity.
• To elucidate the molecular mechanism of action and identify the specific target of the novel compound.

Main Methods:

• In vitro and in vivo testing of a new coumarin compound (DCH) against MRSA.
• Cellular proteome analysis to investigate the mechanism of action.
• Molecular docking, binding affinity assays, and strain comparisons (wild-type vs. ArgR-deficient MRSA) to identify the drug target.

Main Results:

• The coumarin compound DCH demonstrated significant efficacy against MRSA biofilms both in vitro and in vivo.
• DCH exhibits potent antibiofilm activity with no detectable resistance development.
• Proteome analysis indicated that DCH interferes with the arginine catabolic pathway, with ArgR identified as the direct molecular target.

Conclusions:

• DCH is a promising lead compound for developing new anti-MRSA biofilm agents.
• Targeting the bacterial arginine repressor ArgR presents a viable strategy for combating MRSA infections.